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Background: Patients with peripheral vascular disease have been excluded from initial studies of percutaneous suture-
mediated closure devices (SMCD) despite representing a significant proportion of those requiring endovascular
intervention. We sought to determine whether these devices could be safely used in patients with peripheral vascular
disease.
Methods: Patients were stratified into two groups and five subgroups on the basis of indication for arteriography, and they
were prospectively randomized at the end of the procedure to receive either the SMCD or manual compression.
Ankle-brachial index was determined and duplex ultrasound scanning of the accessed femoral artery was performed,
before and after the procedure. Ultrasound data included peak systolic velocity, minimum intraluminal vessel diameter,
and presence or absence of calcified plaque. Time to hemostasis, ambulation, and discharge were recorded, and major or
minor complications were noted.
Results:Of 102 patients included in the study, 52 patients were randomized to receive the SMCD. There was no difference
in ankle-brachial index, minimum intraluminal vessel diameter, or peak systolic velocity in the accessed vessel after closure
with SMCD or manual compression. Time to hemostasis, ambulation, and discharge was significantly less in the SMCD
group (P  .001). Presence of calcified plaque was not associated with complications (P  .146). In the SMCD group,
hemostasis was achieved with 49 of 52 devices (94.2%). There were six complications (5.9%), two of which were major and
required operative intervention. All complications were hemorrhagic and not occlusive. There was no difference in overall
complication rate between SMCD (7.7%) and manual compression (4.0%) groups (P  .678). No infection was noted in
any of the 102 patients.
Conclusions: Suture-mediated percutaneous arterial closure can be safely performed in patients with peripheral vascular
disease, even in the presence of calcified plaque. This closure technique enables shorter time to hemostasis, ambulation,
and hospital discharge. There are observed differences in minor, but not major, complication rates for MC versus
percutaneous arterial closure in patients with peripheral vascular disease, but these differences did not achieve statistical
significance in this small series. (J Vasc Surg 2003;38:263-71.)
Advanced catheter-based technology has led vascular
surgeons to expand their role as endovascular specialists.
Since 1959, when Seldinger introduced his technique of
percutaneous arterial access, femoral access sites have been
managed with manual compression followed by a variable
period of bed rest. Access site complications are the single
greatest cause of morbidity after percutaneous femoral
catheterization procedures. Bleeding complications, most
notably pseudoaneurysm and hematoma, occur in 5% to
10% of patients, and lead to transfusion or surgical repair in
approximately 1.5% of patients.1 With the increased use of
anticoagulant and anti-platelet agents during endovascular
intervention, control of the access site has become an
important focus in every endovascular procedure.
Several percutaneous closure devices have been devel-
oped in the past decade, and four have been approved by
the US Food and Drug Administration for use in human
beings. Three devices rely on a procoagulant agent injected
at the access site for hemostasis. The Perclose device (Red-
wood City, Calif) is a suture-mediated closure device
(SMCD) that does not rely on a collagen plug for hemo-
stasis.2-5 SMCD have been evaluated in two prospective
randomized trials in patients examined for coronary artery
disease or evaluated for coronary artery intervention.1,6
The device was equivalent to manual compression with
regard to complications. Use of the device significantly
reduced the time to ambulation and hospital discharge.
Patients with evidence of peripheral vascular disease, how-
ever, were excluded from these studies. No reliable infor-
mation currently exists regarding use of the Perclose device
in this subset of patients, who represent the majority of
patients referred to a vascular surgeon.
Increasingly, catheter-based vascular procedures are
being performed in patients with peripheral vascular dis-
ease. Many of these patients have diseased femoral vessels
and are likely to sustain a complication from arteriography.
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To investigate the effect, if any, of percutaneous closure
devices on diseased femoral arteries, we designed a prospec-
tive, randomized trial to compare the traditional method of
MC versus use of a SMCD in patients with atherosclerotic
peripheral vascular disease.
Our objective was to prospectively determine the ef-
fects and technical limitations of use of percutaneous
SMCD in randomized patients with peripheral vascular
disease undergoing diagnostic or interventional vascular
procedures.
METHODS
This was a prospective study with randomized block
design. Patients in each stratum were separated into two
main groups, ie, occlusive and nonocclusive disease, and
then divided into five subgroups on the basis of indication
for the endovascular procedure, ie, infrainguinal artery
disease, aortoiliac artery disease, renal artery stenosis or
other artery disease, abdominal aortic aneurysm, and aortic
endograft.
Perclose device. The Perclose device is made up of
two components: a sheath that holds one or two pairs of
needles connected with a suture loop, and a rotating barrel
that is used to accurately position the device before needle
deployment and to guide the needles through the subcu-
taneous tract.6 The 6F device (Techstar; Perclose, Red-
wood City, Calif) delivers two needles and one suture
through the arterial wall, whereas the 8F and 10F devices
(Prostar XL; Perclose) deliver four needles and two sutures.
The two-needle (single suture) device is used to close
arterial puncture sites after diagnostic or interventional
catheterization procedures performed through 5F and 6F
introducer sheaths, and the four-needle device (two su-
tures) is used to achieve hemostasis after interventional
procedures performed through 7F to 10F introducer
sheaths. Details of the closure procedure for standard cath-
eter-based procedures are described elsewhere.1,6 Larger
sheaths require use of a “pre-close” technique, in which a
10F device is deployed at the start of the procedure and the
arteriotomy is made to the requisite sheath size.
All patients referred to our vascular surgery service for
arteriography were offered entry into the study. The study
protocol was approved by the institutional review board.
Patients were separated into two main groups, ie, occlusive
or nonocclusive disease, and then were divided into five
subgroups (blocks) on the basis of indication for an endo-
vascular procedure, ie, infrainguinal disease, aortoiliac dis-
ease, renal artery stenosis or other disease, abdominal aortic
aneurysm, and aortic endograft. End points measured were
changes in accessed vessel, time to hemostasis, time to
ambulation, time to discharge, and complications.
Patients within each stratum were randomized at the
end of the catheter-based procedure to receive either the
SMCD or manual compression. Patients in the aortic en-
dograft subgroup were randomized before aortic en-
dografting to receive either surgical cutdown and subse-
quent open arterial repair or percutaneous closure with a
pre-close technique. This technique has been well-de-
scribed,5 and involves deployment of a 10F closure device
over a wire at the start of the endograft procedure without
tying the sutures. Subsequently the arteriotomy is in-
creased, up to 20 F.
Data were prospectively collected and included demo-
graphics; ankle-brachial index (ABI) before and after the
procedure; duplex ultrasound (US) scanning of the ac-
cessed femoral artery before and after the procedure, to
determine peak systolic velocity (PSV), minimum intralu-
minal vessel diameter (Dmin), and presence or absence of
calcified plaque; time to hemostasis, ambulation, and dis-
charge; and major or minor complications. An SPSS data-
base (statistical software package, version 10.0.05; SPSS
Inc, Chicago, Ill) was created for data collection and statis-
tical analysis.
Standard demographic data were recorded. Procedural
data included time of procedure, intervention, sheath size,
systolic blood pressure, heparin dose, activated clotting
time, and number of access attempts. Time to hemostasis,
ambulation, and discharge was recorded.
Duplex US scanning of the accessed femoral artery was
performed in all patients before and after the endovascular
procedure (Fig 1). The operator was blinded to the results
of preoperative duplex US scanning. Data collected con-
sisted of B-mode images of the common femoral artery in
sagittal and three separate cross-sectional views, from the
inguinal ligament to the femoral bifurcation, with an at-
tempt to clarify presence or absence of calcified plaque in
the anterior and posterior arterial wall. Dmin and PSV were
recorded throughout the entire common femoral artery.
Bilateral ultrasound was routinely performed preopera-
tively, whereas only the randomized vessel was imaged in
postoperatively.
Device failure and operator technical errors were re-
corded. Time to hemostasis was defined as time from
sheath removal to absence of bleeding at the access site.
Time to ambulation was defined as time from sheath re-
moval to ambulation farther than 10 ft. Patients with
amputated limbs and those who were unable to walk were
excluded from this determination. Our institutional policy
for management of femoral access sheaths requires that the
patient remain supine for 4 hours after manual compression
if a 6F or smaller sheath was used and 6 hours if a 7F or
larger sheath was used. All patients that received the SMCD
were allowed to ambulate 1 hour after sheath removal. In
patients who underwent intervention and those who re-
ceived intravenous heparin, activated clotting time was
determined at the end of the procedure. In patients ran-
domized to receive manual compression, the sheath was
not removed until activated clotting time was less than 180
seconds. Activated clotting time was also determined in
patients who received SMCD, but a prolonged value did
not affect the time of sheath removal. Time to discharge
was defined as time from sheath removal to discharge from
the hospital. Time to hemostasis, ambulation, and dis-
charge was not recorded for the aortic endograft subgroup.
Complications were categorized as major or minor.
Major complications were defined as any complication that
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required transfusion of blood products, surgery, or US-
guided compression, or any infection.Minor complications
were defined as hemorrhage that required more than one
dressing change, hematoma, or arteriovenous fistula.
Statistical analysis. Statistical analysis was performed
with the SPSS version 10.0.5 statistical software package.
To compare the difference between SMCD and manual
compression groups, the Student two-sample t test was
used for continuous variables, eg, age and systolic blood
pressure, and the Fisher exact test and Pearson X2 test were
used for categorical variables, eg, gender and comorbid





Fig 1. A, Schema of a normal duplex ultrasound scan of the right common femoral artery. Minimum intraluminal
diameter was measured on proximal (B), middle (C), and distal (D) cross-sectional images after scanning through the
entire artery from inguinal ligament to femoral bifurcation. E, A sagittal view was obtained for determination of
calcified plaque. F, Peak systolic velocity measurements were recorded. Continued.
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after the procedure, repeated measures analysis of variance
was performed for ABI, PSV, and Dmin. Odds ratios were
calculated with the Mantel-Haenszel (log rank) test for
equivalency. Logistic regression analysis was not per-
formed, because of small sample size.
RESULTS
Of 102 patients randomized, 52 patients underwent
percutaneous suture-mediated closure of the femoral artery
access site. The number of patients receiving SMCD per
subgroup are listed in Table I. There was no significant
difference between SMCD and manual compression
groups with regard to patient characteristics or procedural
factors (Tables II, III).
Vessel characteristics are listed in Table IV. There was
no difference in ABI, Dmin, or PSV in the accessed vessel
after closure with SMCDormanual compression. In 67% of
patients (68 of 102) calcified plaque was noted within the
femoral artery (Fig 2), posterior only in 56 patients (82%) and
circumferential in 12 patients. The presence of calcified plaque
was not associated with any complication (P .146).
In the SMCD group, hemostasis was achieved with 49
of 52 devices (94.2%). Three devices (5.8%) failed, due to
suture breakage in one case and sutures that pulled through
the arterial wall in two cases. Two of the three devices were
simply replaced over a guide wire, and hemostasis was
achieved. Wire access was lost with the third device, and
manual compression was applied. All data recorded for
these three patients was analyzed with the SMCD group.
None of the three patients had a major or minor complica-
tion. There were no operator errors noted. In the manual
compression group, 49 of 50 attempts (98%) were success-
ful in achieving hemostasis. One patient required surgery to
repair the femoral artery access site.
In patients who received SMCD, overall time to hemo-
stasis was significantly reduced (P  .001), as was time to
ambulation (P  .001) and time to discharge (P  .001)
(Fig 3).
Overall, there were six complications (5.9%) in this
series (Table V). Major complications that required surgery
developed in one patient in the SMCD group (1.9%) and
one patient in the manual compression group (2.0%) (P 
.678) (Table VI). Both major complications occurred in
patients with nonocclusive disease and absence of calcified
plaque at duplex US scanning. In all four patients who
sustained minor complications, calcified plaque was dem-
onstrated on duplex US scans. Three of these patients were
in the SMCD group. All complications were hemorrhagic
and not occlusive. The only major complication in the
SMCD group was development of a large pseudoaneurysm
after placement of a 16F sheath for aortic endografting.
Excluding the aortic endograft subgroup because of poten-
tial study bias, there were observed differences in compli-
cation rates in the remaining 88 study patients (Table VII).
However, these differences did not achieve statistical sig-
nificance in this small series. In 24 of 102 patients (24%)
intraluminal diameter was less than 5 mm, and all were in
either the infrainguinal disease or aortoiliac disease sub-
group (occlusion group). Fifteen of the 24 patients (62.5%)
received the SMCD. There were no major complications
and only two minor bleeding complications in this group.
No infection was noted in any of the 102 patients. Mean
follow-up was 1.11 years (range, 0.61-1.67 years).
DISCUSSION
With the recent explosion of endovascular therapies,
definitive control of the femoral artery access site has be-
Table I. Group and subgroup populations and number







Occlusive disease Infrainguinal 29 15 52
Aortoiliac 27 13 48






Endograft 14 7 50
102 52 51
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come essential. Although various closure devices exist, per-
cutaneous suture-mediated closure is the most attractive to
vascular surgeons.
The Perclose SMCD was compared with manual com-
pression in a randomized trial of 600 patients conducted by
Gerckens et al.6 The major study end points included
incidence of complications and time to ambulation after the
procedure. The study included both diagnostic and inter-
ventional coronary procedures. A significant reduction in
time to achieve hemostasis and time to ambulation was
associated with use of the device. The incidence of compli-
cations was similar in the overall population (5.7% for
SMCD vs 11.3% for manual compression) and in the inter-
ventional subset (8.4% for SMCD vs 9.6% for manual
compression). There was, however, a significant reduction
in incidence of complications in the diagnostic procedure
subset (4.4% for SMCD vs 12.1% for manual compression;
P  .05). Their conclusions were that the SMCD is a safe
alternative to manual compression, with faster hemostasis
and return to ambulation and potential reduction in access
site complications.6
Baim et al1 published the results of the Suture to
Ambulate and Discharge trials (STAND I and STAND II),
which assessed suture-mediated closure of the femoral ac-
cess site after cardiac catheterization. STAND I evaluated
the 6F Techstar device in 200 patients undergoing diag-
nostic procedures. Successful hemostasis was achieved in
99% of patients in a median of 13 minutes, with a 1% rate of
major complication. The follow-up STAND II trial ran-
domized 515 patients undergoing diagnostic or interven-
tional procedures to use of the 8F or 10F Prostar XL device
versus manual compression. Successful suture-mediated
hemostasis was achieved in 97.6% of patients, compared
Table II. Patient characteristics
SMCD (n  52) MC (n  50)
Pn % n %
Mean age (y) (mean  SD) 69.4  9.3 71.4  8.8 .831*
Male gender 40 77 34 68 .377
Comorbid condition
Hypertension 44 85 40 80 .609
Diabetes 12 23 18 36 .194
ASPVD 49 94 50 100 .243
Tobacco use 29 56 21 42 .173
Hyperlipidemia 33 64 30 60 .839
Angina 4 8 2 4 .678
Myocardial infarction 14 27 14 28 1.000
Pre-operative anticoagulant
Aspirin 36 69 33 66 .833
Clopidogrel 3 6 3 6 1.000
Warfarin 2 4 2 4 1.000
Heparin 1 2 2 4 .614
Low molecular weight heparin 1 2 1 2 1.000
Pre-operative antibiotic 28 54 26 52 1.000
Previous arteriography 34 65 29 58 .791
SMCD, Suture mediated closure device; MC, manual compression; ASPVD, atherosclerotic peripheral venous disease.
*Two independent sample t test; all other P values, Fisher exact test.




(n  50) P










Access/attempts (m) 1.38 1.76 .080†
SMCD, Suture-mediated closure device; MC, manual compression.
*Fisher exact test.
†Student t test.
‡Univariate analysis of variance.
§Only for those patient undergoing intervention.
Fig 3. Overall time to hemostasis, ambulation, and discharge in
102 patients who received either a suture-mediated closure device
(SMCD) or manual compression (MC).
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with 98.9% of patients with manual compression (differ-
ence not significant). Major complication rates were 2.4%
and 1.1%, respectively, and met the Blackwelder test for
equivalency (P  .05). Median time to hemostasis and
ambulation were significantly shorter for suture-mediated
closure (each, P  .01).
Each of these prospective studies excluded patients
with existing peripheral vascular disease. All patients with
preexisting vascular complication, femoral artery smaller
than 5 mm in diameter, femoral artery stenosis greater than
50%, fluoroscopically visible calcium, posterior wall punc-
ture, or coagulopathy were excluded.1 These criteria typi-
cally describe a substantial proportion of patients undergo-
ing endovascular procedures performed by a vascular
surgeon.
Only one study7 evaluated use of suture-mediated per-
cutaneous closure in a subset of patients with peripheral
vascular disease. Eighty consecutive patients who had un-
Table IV. Vessel characteristics in 102 patients
Suture-mediated closure device (n  52) Manual compression (n  50)
Parameter Pre Post P* Parameter Pre Post P*
ABI 0.82 0.86† .434 ABI 0.87 0.90† .434
PSV (cm/s) 116.7 117.3‡ .353 PSV (cm/s) 107.4 123.3‡ .583
Dmin (cm) (range, 0.28-1.07) 0.656 0.663
§ .833 Dmin (cm) (range, 0.29-1.26) 0.664 0.680
§ .699
Pre, Preoperative value; Post, postoperative value; ABI, ankle-brachial index; PSV, peak systolic velocity; Dmin, minimum intraluminal diameter.




Fig 2. Representative sagittal and transverse B-mode images of both anterior and posterior plaque (A) or posterior
plaque only (B). Note that minimum intraluminal diameter in the artery with posterior plaque only was 0.28 cm. Both
incisions were successfully closed with a percutaneous suture-mediated closure device, without subsequent procedure-
related complications. The presence of plaque was not associated with increased risk for complications.
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dergone femoropopliteal angioplasty underwent suture-
mediated percutaneous closure with 6F or 8F devices.
Hemostasis was achieved in 96% of patients. One patient
(1.25%) required blood transfusion and surgery despite an
initial successful outcome. Minor complications (three
small hematomas, one pseudoaneurysm, one small lym-
phatic fistula) occurred in 5 patients (6%).7 All three hema-
tomas and the pseudoaneurysm were discovered only at
routine post-procedure duplex US scanning; all subse-
quently resolved. This is the only study of SMCD in a
subset of patients with peripheral vascular disease, albeit
neither randomized nor controlled, and demonstrated a
major complication rate of 1.25%, compared with 2.4% in
the STAND II trial.
The current study provides compelling evidence that
percutaneous suture-mediated closure of femoral access
sites in patients with peripheral vascular disease is both safe
and effective. Our patients represent a cohort requiring
catheter-based intervention to treat non-cardiac-related
vascular disease. We calculated a requisite of 374 patients,
with 187 patients per study arm, to reach a statistical power
of 0.8 with 95% confidence interval, on the basis of a
device-related complication rate of 2.4%. We acknowledge
the risk for type II error with our small sample size, and
Table V. Complications listed according to subgroup and method of hemostasis
Subgroup Method
Major complications
Hemorrhage requiring blood transfusion and surgery RAS/other MC
Pseudoaneurysm requiring surgery Endograft SMCD
Minor complications
Small pseudoaneurysm spontaneously thrombosed Infrainguinal SMCD
Hemarrhage reguiring more than 1 dressing change Aortoiliac SMCD
Hemorrhage with hematoma 5 cm AAA MC
Hemorrhage with hematoma 5 cm Aortoiliac SMCD
SMCD, Suture-mediated closure device; MC, manual compression; RAS, renal artery stenosis; AAA, abdominal aortic aneurysm.
Table VI. Complications in each group and subgroup, based on SMCD or MC













(n  14) n %
Major complications†
SMCD 0 0 0 0 1 1/52 1.9
MC 0 0 1 0 0 1/50 2.0
Minor complications
SMCD 1 2 0 0 0 3/52 5.8
MC 0 0 0 1 0 1/50 2.0
Total 1 2 1 1 1 6 5.9 0.81
SMCD, Suture-mediated closure device; MC, manual compression; RAS, renal artery stenosis; AAA, abdominal aortic aneurysm.
*Mantel-Haenszel test, SMCD vs MC.
†Note that all major complications occurred in patients with nonocclusive disease.
Table VII. Complication rates excluding aortic endogroup subgroup, based on SMCD or MC











(n  17) n %
Major complications
SMCD 0 0 0 0 0/45 0.0 .49
MC 0 0 1 0 1/43 2.3 .49
Minor complications
SMCD 1 2 0 0 3/45 6.7 .62
MC 0 0 0 1 1/43 2.3
Total 1 2 1 1 5 5.7 1.00
SMCD, Suture-mediated closure device; MC, manual compression; RAS, renal artery stenosis; AAA, abdominal aortic aneurysm.
*Mantel-Haenszel test, SMCD vs MC.
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 2 Starnes et al 269
therefore we recommend caution in interpretation of lack
of difference related to complication rate.
Device success in this series was 94.2%, and device
failure did not preclude successful closure. Simple replace-
ment with a new device over a guide wire enabled successful
closure in two of three patients. All device failures were due
to either suture breakage or the sutures pulling through the
arterial wall. In addition, device failure did not lead to
increased risk for complications. Distinction must be made
between the described devices and the 6F Closer device
(Perclose, Redwood City, Calif) currently on the market.
We did not use any Closer devices during this study.
One might expect a SMCD to narrow the vessel from
baseline and cause subsequent occlusive complications, eg,
acute arterial occlusion. We did not find this to be true. All
complications in our study were hemorrhagic, not occlu-
sive. Meticulous duplex US scanning performed both be-
fore and after placement of the Perclose device demon-
strated no change in Dmin or PSV of the accessed vessel;
ABI also was unaffected.
A listed contraindication for use of the Perclose device
is presence of calcified plaque within the femoral artery.
Our findings do not support this as a contraindication to
use of the device. Two thirds of our patients had evidence of
calcified plaque in the femoral vessels, with the majority
(82%) being along the posterior wall. Of interest, both
major complications in this series occurred in patients with-
out evidence of calcified plaque. The recognition that the
most arterial calcified plaque is located posteriorly and the
suture is routinely placed on the anterior surface of the
artery would partially explain the absence of major compli-
cations in this subset of patients. We have successfully used
percutaneous closure in arteries with anterior calcification,
and we do not believe this to be a contraindication for use
of the device.
Previous studies have proved shorter time to hemosta-
sis, ambulation, and discharge with use of the Perclose
device.1,6 These findings, although statistically significant,
were of less interest to us. Our study design had built-in
bias from the beginning in that, per institutional policy,
patients were not allowed to ambulate for a predetermined
amount of time after receiving manual compression. Pa-
tients who received SMCD were allowed to get out of bed
1 hour after device placement. Decreasing the time to
ambulation and hemostasis does not necessarily represent a
net benefit if there is a demonstrated increase in incidence
of complications.
Of particular interest is the subset of patients in this
series who underwent an interventional procedure. All of
these patients received intravenous unfractionated heparin
at the time of the procedure. In those patients who received
SMCD, mean activated clotting time was 231 seconds on
removal of the sheath. These patients were ambulating on
average 1.6 hours after sheath removal, whereas those who
underwent manual compression were ambulating on aver-
age 5.1 hours after sheath removal. Time required for
correction of activated clotting time in the manual com-
pression group was significantly increased, compared with
the SMCD group, and subsequently delayed sheath re-
moval in the manual compression group.
Seven of 14 patients stratified to the aortic endograft
subgroup received an SMCD with a pre-close technique.
The only major complication of device placement occurred
in this subgroup. This patient underwent percutaneous
arterial closure after placement of a 16F sheath for aortic
endografting. Postoperatively, a large pseudoaneurysm de-
veloped that required operative repair. Rachel et al8 re-
ported their experience with percutaneous suture-mediated
closure of large femoral access sites in conjunction with
aortic endografting. No pseudoaneurysm was associated
with percutaneous closure. A higher success rate was
achieved with devices delivered through 16F or smaller
sheaths. These authors concluded that procedural success
for percutaneous aortic aneurysm repair is affected by
sheath size.
Surgical cutdown is an alternative method of arterial
closure, and was used in seven patients in the aortic en-
dograft subgroup in our study. Data for this subgroup of 14
patients were included in the analysis of subgroup charac-
teristics and arterial hemodynamics, because of the ran-
dom-block design of the study and because each patient
served as his or her own control with regard to noninvasive
arterial measurements. However, including these patients
in assessment of overall complication rates introduces sig-
nificant study bias. When the endograft subgroup was
excluded, there were observed differences in complication
rate in the remaining 88 patients, but these differences did
not achieve statistical significance in this small series of
patients.
Anecdotal reports abound in the literature regarding
risk for infection with use of SMCD.9-12 We believe this to
be evidence of the overall learning curve experienced after
introduction of the Perclose device into clinical use. We
believe that specific attention must be paid to cutting the
suture ends well beneath the surface of the skin, because the
braided material may act as a conduit for infectious compli-
cations. Carey et al13 published data for 1004 consecutively
placed Perclose devices and noted four infections (0.04%).
Of note, however, is that there were no infections in a
comparable group of patients in whom only manual com-
pression was used. There were no infections in our series of
102 patients. The consequence of arterial infection can be
disastrous9,13; for this reason, we recommend that this
SMCD be used judiciously. Emphasis must always be
placed on sterile technique during any endovascular proce-
dure. We advocate close adherence to sterile technique,
cutting the device sutures well below the skin surface, and
use of antibiotic ointment at the access site.
Percutaneous SMCD have a role in management of the
femoral artery access site in patients with peripheral vascular
disease undergoing catheter-based intervention. Specifi-
cally, we believe this device to be most useful in patients
undergoing catheter-based intervention and in those re-
ceiving large doses of anticoagulant agents. The device is
also extremely useful in diagnostic procedures in patients
with a history of severe low back pain or orthopnea, in
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whom a prolonged period of lying supine would be diffi-
cult. We also suggest an element of caution in using this
device in patients with diabetes mellitus and systemic evi-
dence of bacteremia or infection. Manual compression is
perfectly acceptable, and it should remain the hemostatic
method of choice in diagnostic procedures in which 5F or
6F sheaths are used.
CONCLUSIONS
Percutaneous suture-mediated closure can be safely
performed in patients with peripheral vascular disease, even
in the presence of calcified plaque. Intraluminal vessel
diameter less than 5mm is not a prohibitive factor for use of
this device.We observed no significant differences in overall
complication rate between manual compression and percu-
taneous arterial closure in patients with peripheral vascular
disease, but we recommend caution in data interpretation,
because of our small sample size. Suture-mediated percu-
taneous arterial closure enables shorter time to hemostasis,
ambulation, and hospital discharge, and the method is
clearly beneficial in patients receiving anticoagulant agents
during catheter-based interventions.
We thank Jinua Wang and Michelle Raebner for assis-
tance in the vascular laboratory. Without their expertise,
this study would not have been possible.
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